A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Inclusion Criteria:

Definitive diagnosis of unresectable locally advanced or metastatic RCC with clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior treatment in the metastatic setting
Evaluable Memorial Sloan Kettering Cancer Center risk score
Measurable disease, as defined by RECIST v1.1
Karnofsky performance status greater than or equal to 70%
Adequate hematologic and end-organ function prior to randomization

Exclusion Criteria:

Disease-Specific Exclusions:

Radiotherapy for RCC within 14 days prior to treatment
Active central nervous system disease
Uncontrolled pleural effusion, pericardial effusion, or ascites
Uncontrolled hypercalcemia
Any other malignancies within 5 years except for low-risk prostate cancer or those with negligible risk of metastasis or death

General Medical Exclusions:

Life expectancy less than 12 weeks
Participation in another experimental drug study within 4 weeks prior to treatment
Pregnant or lactating women
Known hypersensitivity to any component of atezolizumab or other study medication
History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes mellitus
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis
Positive human immunodeficiency virus test
Active or chronic hepatitis B or C
Severe infections within 4 weeks prior to treatment
Exposure to oral or IV antibiotics within 2 weeks prior to treatment
Live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination participants must agree not to receive live, attenuated influenza vaccine within 4 weeks prior to treatment, during treatment or within 5 months following the last dose)
Significant cardiovascular disease
Prior allogeneic stem cell or solid organ transplantation

Exclusion Criteria Related to Medications:

Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment

Bevacizumab- and Sunitinib-Specific Exclusions:

History of hypertensive crisis or hypertensive encephalopathy
Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds